Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Age is the key risk factor for diseases and disabilities of the elderly. Efforts to tackle age-
related diseases and increase healthspan have suggested targeting the ageing process …

Disease modeling and target identification are the most crucial initial steps in drug
discovery, and influence the probability of success at every step of drug development …

Cellular senescence is a key component of human aging that can be induced by a range of
stimuli, including DNA damage, cellular stress, telomere shortening, and the activation of …

The past two centuries have witnessed an unprecedented rise in human life expectancy.
Sustaining longer lives with reduced periods of disability will require an understanding of the …

The pursuit to discover the fundamental biology and mechanisms of aging within the context
of the physical and social environment is critical to designing interventions to prevent and …

As the size of genome-wide association studies increase, the number of associated trait loci
identified inevitably increase. One welcomes this if it allows the better delineation of the …

Ageing phenotypes, such as years lived in good health (healthspan), total years lived
(lifespan), and survival until an exceptional old age (longevity), are of interest to us all but …

Rates of atherosclerotic cardiovascular diseases (CVD) in the Western world have
spectacularly decreased over the past 50 years. However, a substantial proportion of high …

The development of clinical interventions that significantly improve human healthspan
requires robust markers of biological age as well as thoughtful therapeutic targets. To …